Literature DB >> 20166963

Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.

Guang Rui Luo1, Wei Dong Le.   

Abstract

The homeostasis of the protein synthesis and degradation is crucial for cell survival. Most age-related neurodegenerative diseases are characterized by accumulation of aberrant protein aggregates in affected brain regions. The principal routes of intracellular protein metabolism are the ubiquitin proteasome system (UPS) and the autophagy-lysosome pathway (ALP). They collaborate to degrade wasted proteins and interact each other to cope with the pathological conditions, in which molecular chaperones play collective roles by assisting the protein targeting to the proteasome or autophagy. It is known that intracellular protein degradation functions are decreased with aging in many tissues and organs. Failure to perform their functions could underlie the inability of cells to adapt to stress conditions, lead to accelerated course of misfolding protein deposit and the inclusion body formation, and eventually result in neurodegeneration.One of the functions of the molecular chaperones is to help the new synthesized or the misfolding toxic proteins fold to their native and nontoxic formation, as our common conception. In this review, we analyze the recent perceptions and findings of molecular chaperones biology in the two degradation pathways and their pathological attribution in several neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and others. It is worthy noticing that some of the HSPs can not only block the protein aggregation in the early stages, but also have promising effect on attenuating the formation of fibrils. Further more, when the degradation pathways are too weak to degrade all the toxic soluble proteins, molecular chaperones can also help to sequenstrate the toxic proteins into inclusion bodies. However, whether it is good or bad is still unclear. Therefore, the study of HSPs might shed new light on not only the mechanisms of protein synthesis and degradation, but also the possible therapeutic targets of fibril formation associating diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166963     DOI: 10.2174/138920110790909740

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  13 in total

Review 1.  The fine-tuning of proteolytic pathways in Alzheimer's disease.

Authors:  Valentina Cecarini; Laura Bonfili; Massimiliano Cuccioloni; Matteo Mozzicafreddo; Mauro Angeletti; Jeffrey N Keller; Anna Maria Eleuteri
Journal:  Cell Mol Life Sci       Date:  2016-04-27       Impact factor: 9.261

2.  Motor neuron disease due to neuropathy target esterase mutation: enzyme analysis of fibroblasts from human subjects yields insights into pathogenesis.

Authors:  Nichole D Hein; Shirley R Rainier; Rudy J Richardson; John K Fink
Journal:  Toxicol Lett       Date:  2010-09-17       Impact factor: 4.372

3.  Cell-to-cell transmission of α-synuclein aggregates.

Authors:  Seung-Jae Lee; Paula Desplats; He-Jin Lee; Brian Spencer; Eliezer Masliah
Journal:  Methods Mol Biol       Date:  2012

4.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Authors:  Keith T Gagnon; Hannah M Pendergraff; Glen F Deleavey; Eric E Swayze; Pierre Potier; John Randolph; Eric B Roesch; Jyoti Chattopadhyaya; Masad J Damha; C Frank Bennett; Christophe Montaillier; Marc Lemaitre; David R Corey
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

Review 5.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

6.  Therapeutic approaches to delay the onset of Alzheimer's disease.

Authors:  Raj Kumar; Hani Atamna
Journal:  J Aging Res       Date:  2011-03-03

7.  Mitochondrial enzymes are protected from stress-induced aggregation by mitochondrial chaperones and the Pim1/LON protease.

Authors:  Tom Bender; Ilka Lewrenz; Sebastian Franken; Catherina Baitzel; Wolfgang Voos
Journal:  Mol Biol Cell       Date:  2011-01-05       Impact factor: 4.138

Review 8.  Heat shock protein 70 in Alzheimer's disease.

Authors:  Rui-Chun Lu; Meng-Shan Tan; Hao Wang; An-Mu Xie; Jin-Tai Yu; Lan Tan
Journal:  Biomed Res Int       Date:  2014-11-06       Impact factor: 3.411

Review 9.  Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases.

Authors:  Monimoy Banerjee; Ishita Hatial; Bradley M Keegan; Brian S J Blagg
Journal:  Pharmacol Ther       Date:  2020-11-24       Impact factor: 12.310

10.  TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells.

Authors:  Sofia Ranta-Aho; Niina Piippo; Eveliina Korhonen; Kai Kaarniranta; Maria Hytti; Anu Kauppinen
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.